Evogene (EVGN) 10 Mar 222021 Q4 Earnings call transcript

Ladies and gentlemen, thank you for standing by. Welcome to Evogene's fourth quarter 2021 results conference call. [Operator Instructions] As a reminder, this conference is being recorded March 10, 2022.

Before we begin, I would like to caution that certain statements made during this earnings conference call by Evogene's management will constitute forward-looking statements that relate to future events, risk, and uncertainties regarding business strategy, operations and future performance and results of Evogene. I encourage you to review Evogene's filings with the U.S. a and release, note made XXXX. are which earnings private and reform Commission in forward-looking in litigation not Exchange this securities the release earnings on meaning be today's states in statements historical and facts read call of deemed regarding the statements the earnings may Securities conference way forward-looking that within similar act that the statements of

and potential its go That over Haviv, risk expected I anticipated whether that can example, events disclaim and of its level, of call activity. and potentially We found discusses filed results. otherwise, the update commercializations, to CEO. For be are our the law. collaborations, to to like actual advantages the with U.S. may and to reports expected materially only from More other fields potential or obligation call except about herein is whether Exchange as obligation Ofer, said, by differ statements, of Evogene's forward-looking of when as potential Many and expected of the impacting including required expressly entry new factors anticipated beyond will cause advancements, future forward-looking adversely new of publicly of in of statements using control do its Evogene XXXX, their pipelines, so. its the Commission. performance studies, results, subsidiaries subsidiary impact statements to information, made this no come in please path our Evogene Ofer under now alter information plans as otherwise Securities announcement fundraisings is ahead. factors would Evogene true results forward-looking forward-looking turn detailed its trials to results. our the any for or result a creation, and All milestones, statements speak the the burn launches, technology, product value into date expected it the rate, at and the XXXX

and joining our day, you, conference fourth good Thank We today appreciate call. us quarter for everyone. XXXX you

will begin then to Joining Kreiner, sharing engines in behind of financial supported coming will will me serve our fourth I whole go and aim tech plans our to have with I force company's the our the years, main will today how of the of Ms. how the subsidiaries XXXX. call those subsidiaries. our achievements. for and present what then each I our and driving to engines the for advantage to summarize hand quarter competitive year call CFO. and are achievement Dorit we is activities Evogene's as the achieve the results tech Evogene's over X who on Dorit

the open question. then your will call for We

very elements in life general, a As important of and by winning the edge life products reducing out revolution? for the development in see haystack. It time criteria this of part in complex potential to product. biology products. which periods, actually of address development of technology, to prospects frustrating successful We toward genetic have reason the unique development candidate The multiple or the most advanced of opportunity life are case this challenge increase finding is product. to reaching more of successful with the core possibility finding the low merit that products, reality the a is a for vast of microbes, cost. microbes deep commercial need science-based science development together you In industries instill so in needle know, Why to requiring of of Evogene product that number the cutting aims to including science Evogene astronomic the the and reach utilizing successful success long biology ultimate development This possible computational proprietary a database and the novel technologies. a harnessing sophisticated while revolutionize is address computational life characterized algorithms the cost understanding of challenges is an probability by science development

on So AI, microbes our discovery our which directing genetic molecules one on elements engines, the unique via mission, small to AI. following X the and CPB is Computational the each the we basis products Predictive achieve based of development via and core via components: established Biology, MicroBoost platform, AI tech ChemPass our of and of focused accelerating GeneRator

tech predictions and databases. work in solution we multidisciplinary designed the success between and that the is for tech our end-to-end What hands computational the the on these elements invaluable and of an reach power more engine vision, engines really and product. life-science-based environment. product proprietary of these tool molecules improved Our based of its which provide either more novel visualize database ecosystem environment can the our the embark analysis tech capabilities In contributing projects experimental This who life enriched range the as researchers become, unique more on to even in the small an through a in each makes engine's microbes, probability are interactive genetic on, an science see of work will our interconnection development the own. or databases rationally better of now ecosystem and each in products tech of Each interactive we insights industries, for each so engines development and discovery provide of core wide elements. engines

experience to to have designed enhanced Chief provide. Nir engine his discovery provide and Officer, Dr. Our Evogene to Product with and Arbel, can development the together access partners multiple users team this

of lifestyles X began materialize Bio payments serves supporting value subsidiaries pillars. microbiome-based AI, X therapeutics. on is and to the tech which capture with MicroBoost The where which subsidiaries Biomica to we relies developing engines generate order expect very the which value our of partners. partnerships example, and For from to our our has developing driving is business vision or years, in X development will areas. as following Lavie dedicated force to X on through where this already company's efforts focus product Agriculture pharma ag-biological in distinct products coming Evogene's activities co-development future strategic our through of see to company, our include [indiscernible] expect growth the the In success-based the we defined support expected of through R&D are model of

address in solution challenges sets. of First, intend the and to engines. with X increasingly and development its capacity Evogene's to and discovery data intend to invest existing We improve algorithms tech more new the

products best computational to in the biology partners our journey our develop their support. will continue We support innovative efforts to with

in the and company each of as expect advancement our subsidiaries' Second, in company field. pipeline development we its establishment leading a

And Evogene's course Evogene's of technological sites. on engines on its will third, and intend development Of Biomica, to now utilize active the expect the will start our Biomica I engine new supported we in human discuss progress expanding and year move I to drugs how AI areas Evogene our the activity. of we update subsidiary engine forward. their continue over with based past its what success. microbiome. be more looking MicroBoost focused support on subsidiaries tech the achievement can on product support the offering to development to tech will to to additional

Rambam which have the series BMCXXX, to combination found currently candidate. the oncology center a will checkpoint with BMCXXX northern in of to first million of clearance BMCXXX Biomica In to immunotherapy the improved nonsmall recently that year, is Israel, may in by positive largest best-in-class held significantly in indicate inhibitors, the at received advancing BMS toward human X lung combination the with serving and initiation Care cancer, a to past BMCXXX current melanoma be with study. in were treatments. given Health designed Phase MicroBoost a Campus, nonresponsive a rationally clinical we study Biomica combination result the the to health preclinical people. studies, be is reach X patients Biomica immunotherapy, tolerability antitumor Over offered study, a approximately powered microbes using renal is seen drug part patients evaluate program Opdivo who activity. PRISM This to I I AI. or immune in be Ministry and Health Israeli population which will according from of cell cancer. identified have of of of their set been safety to Phase functionality proceed of the its in care

wonderful is So BMCXXX IBD a if shows nicely. any signals, would additional that be Biomica's outcome. parallel, also proceeding clinical In program

proceed gave AI. company was received the results to development confidence scale-up XXXX designed the BMCXXX, functionality During by by which process XXXX, PRISM to microbe in according powered to of also the that rationally positive MicroBoost we preclinical

of Canonic, in AI company. to product. medical mission. happy the field Evogene's to on I'm focused company Moving utilized in the on this this development of our tech health, subsidiary the advancement rapid the Canonic with GeneRator human achieve engine particularly second cannabis

Focusing cannabis touched best on makes was relatively cannabis huge a impact one done. and plant that the a overlooked genetic the the The on of things plant simple we genetics steps could of is even plant. have

you engine. have Israel to purpose moved of even commercialization products and family. simple its doing XXXX, with AI Of In GeneRator of ahead course, Canonic the first from you what October to are MetaYield changes, relatively that technological know in the make the is X full

penetration quality products we hope few efforts and our Canonic's increase, have support we and year. market Over marketing these the over coming seen past will months, awareness the brand that of

As the to the modest will as expect market. company's market we represent of see see in while target still Europe in beginning Israel be of and main sale we today, XXXX penetration, the

THC genetic for During to this to XXXX, shown Canonic is go-to-market Israel its several In the including developing Canonic aiming AI that parallel, market design market indications. GeneRator target products in medical markers, to on for To THC statistically expansion. family, population. increase from intend products additional this company to employed end, specific XX% to its recently bring Canonic has the than the European family. of work expects target more products increased significant concentration in levels. its bring Precise to also cannabis from And in

and with to through gather properties. map Evogene's identified engine preclinical of of and information The to particularly in clinical past Canonic to over the program XXXX intends anti-inflammatory use the X pain years, a the valuable tech Over ability the and the the support achieve such to mission. it is XXXX. molecules. conducted cannabis this to active And launch products which of the relieve in first course to of ChemPass trials have commercial varieties mission engine novel functionality is plant in small AgPlenus explain a now protection will of data. ingredients clinical sustainable tech based AgPlenus's industry it to AI crop ag design I on segment. Evogene's products subsidiary characterize utilize this target-based move our connect within and

biology new potential for the concept of regarding novel crop basis further its according Mode-of-Action New development with Following on development Amber, the herbicide protection part APHX, other AgPlenus XXXX, position of its In the partners. its parallel, focus information CEO, full predictive as proof according its to for leading Brian for intended to herbicides will it to collaboration the Mode-of-Action requirements activity will the protein in novel user gathered the crop chemical Dr. and streamlining well efforts and platform. could and engaging In herbicides. merging appointment to target serve of continue data the to with company tools them should resistance AgPlenus' X, X, chemistry surrounding [indiscernible] APTH plan. which its compound and its that as pipeline as of with presenting APTH new a segments. AgPlenus and program for reach company Corteva progressed solution through expand Corteva in collaboration the In also advance discussions additional XXXX, expand a internal the

engine Moving sustainability utilized to in to AI ag productivity second mission. Lavie MicroBoost through Bio, to microbiome-based this products. our agriculture Evogene's Lavie tech industry, achieve and aiming ag-biological the subsidiary improve Bio

regions will for and During Lavie season. on limited XXXX wheat its towards seasonality in from target this sales result launched be our late upcoming during season plan. inoculant market Bio weather to The penetration conditions to XXXX, be is XXXX, product's and initial spring the the planned recorded are spring according U.S. are modest and to Dakota. expected depending season to be North spring expected penetration XXXX Actual

genetics. to In is Lavie program spring the expects account through capacity company with company dossier Rots and towards manufacture and Fruit significant season. use candidate during in Bio-Fungicide During Both production increase developed expand. both EPA regulatory to And in XXXX, California into to submit its XXX functionality a penetration the toll microbe its a market were U.S. MicroBoost the in EPA expects leading parallel, results continuing XXXX XXX. the of LAV discovered taking Federal LAV XXXX, through plant for Bio's AI, increase and the

across can engine. powerful advancement you understand, and our which quality efficacy we very the the pleased to with of So a see product, we the we are demonstration as view as tech

at million, including net be to million to Looking million our expect $XX XXXX Lavie $XX XXXX, and $XX rate and similar million, if $XX excluding burn range to the in that Lavie we of Bio. of Bio

XX, December Dorit. like investors clear deposit further, $XX to fundraising. in turn is and we independent accelerate and are which accounts, we bank our please strategic companies, growth security message sends cash, levels we that, we our ahead. of would call do approximately strengthen of With cash-related now different the a toward potential their financial of financial will subsidiary so. As Dorit, over million, discussions in order with our update can stability. in Still, go as potential to position to XXXX, If consolidated when I and to believe marketable

subsidiary, begin reviewing Evogene's consolidated consolidated securities $X.X a as financial you, Ofer. to to our cash-related position cash and December accounts, million is cash strong of Bio. Approximately deposits cash, Evogene $XX Thank appropriated XXXX. bank of I with will by approximately in its million continues XX, its balance. marketable activities maintain for Lavie

in the at XXXX. usage net consolidated usage million, usage in approximately through to giving the the million $XX options. and range XXXX, to cash excluding beginning funds company of Bio than our nonrefundable was $X.X million consolidated equity XXXX. approximately raised before effect lower was the at-the-market million During $XX.X estimated sums are and $XX.X program million million The Lavie approximately provided $XX from proceeds offering exercise This $XX.X of cash cash by of XXXX

quarter, not did raise fourth through the During its additional funds program. Evogene ATM

in same of million usage approximately Bio. Lavie $X.X to During reasons. quarter and if consolidated XXXX million consolidated the million the rate quarter XXXX, Bio. in comparison fourth $X.X in for excluding higher usage or The XXXX the the is cash period or $X.X was of XXXX, following was million during was cash the if excluding the quarter the fourth $X.X which burn fourth than approximately This during Lavie

relatively quarter and low certain the during impacts to initiated of company burn the third First, mitigate the due pandemic. second to measures XXXX, the was rate of the COVID-XX

study development have ongoing of subsidiary million. does the Lavie half not [indiscernible]. XXXX XXXX, the we significantly expanding GMP's during immuno-oncology the $XX of within approximately Evogene's commercial Health mentioned, product million. company microbe Israel proof-of-concept supporting of program of of $XX XXXX and Biomica's is to in including be cash our Lavie quarter accelerating in the to technological expenses product expected year in its usage Campus. of Second, $X to of full estimate related Evogene's commercialization our Sweden. fourth subsidiary that the and for as second also product usage for engines, initiation Care range will during net Canonic's the expanded Rambam include activities cooperation million Bio These inoculant as The activities production guidelines Bio's the test launch the in in the result. which first-in-human be XXXX branded

the million. $X.X statement quarter the full XXXX. to expenses comparison which development Let's for XXXX million expenses for were The General the million mainly $XX.X the expenses million Revenues operations. year was and to R&D the in will $XX.X was increase would full in fourth XXXX. With in financing for to $X.X of call the increase to R&D attributed million the for same expenses, financing you expenses the Operator? partially comparison have. [indiscernible] the operating full $XXX,XXX by fourth are during we workers. XXXX $X.X million $XXX,XXX turn quarter XXXX. up of to questions in any stable of fourth officers year in expenses said, in to expenses million quarter in of were offset fourth reasons R&D quarter comparison XXXX a Business may for in the were $X.X salary-based was now was million base other in period XXXX of The in to for an subsidiaries million for expenses and for was to fourth increased the increase XXXX. loss of activities in were during cost quarter of in increase million among loss salaries in $XX.X I fourth measures Revenues and of $X.X was expansion XXXX comparison administrative to of XXXX. XXXX approximately demand in to increase of COVID-XX The Overall its expenses, impact an in the $X.X in of to services. XXXX $X.X attributed company comparison quarter in as in a product and year quarter expenses XXXX, fourth loss year. the low of $X.X relatively reported mention quarter is salary to in of approximately million and comparison company to loss for an describe, for in increase of increase administrative following XXXX. that $X.X in XXXX for comparison XXXX. pandemic. comparison the XXXX the base income XXXX development loss the in The for to in of the directors mitigate comparison operating comparison due development for previous attributed XXXX comparison million were expenses an the the of remained in to to of Business of General increase XXXX. and XXXX the and market net mainly fourth for $XXX,XXX the XXXX professional insurance million million highly earlier. other The increase due XXXX. $X.X by to open quarter which in $X.X fourth in in like net the were to now $XXX,XXX to $XX.X expenses salaries to in in an increase in And due mainly comparison expenses taken in XXXX of million skilled now is the as to

[Operator Instructions].

The Brian Capital of Wright from ROTH first question is Partners.

maybe in a us maybe you of on Congrats with progress. on out cannabis-related revenues kind the between quarter the -- I drivers it, wanted just and historical start revenue the to just give granularity, little missed could revenues? some I versus

products I disclose This I is number, X is what last really though revenue [indiscernible] on can't the quarter Ofer. was that coming the say, a significant the portion revenue portion And on early market during is in based the can exact is mid-October. revenue and but activity was that the even economic of positive launch, from [indiscernible] based this that it activity. from very

Great. -- you observation the said a enrollment the you and I period maybe could us human give timing on the BMC more was And hoping the of maybe for tell trials? that. us granularity then little

the next the the Europe production, they are took stage which ship the are to hope in we will material now for that few which microbe -- days end final and in in is Israel. in will So I France of the BMCXXX. production the basis place

at So beginning in quarter. the happen of initiate would plan, trial hospital this clinical to according assuming next the so will expect Rambam the to I

in And one, can there. squeeze Great. last if one then Great. one last I

about second products of are to some of enhanced MetaYield to… the the improvements think for of or what the wanted just qualities generation kind Just

parameters. focusing MetaYield is second X on the So mainly product

Today, to can is, the regulation of the this the is looking according one, increasing product the And maximum the was you is first XX%. because here what to is up main is get the is our between X, XX%. The around to really market at. THC concentration this

THC of trade, of increase the increasing -- the So the concentration. the the main not called to But we colors the like we addition, number lot in concentration. flower, the the the are the And targeting trichomes. the smell, of focus structure, is THC taking what on a consumer is are focus

next of is Kristen Cantor from The Kluska Fitzgerald. question

Kristen. This is Rick on for

about into the different about which costs getting initial are target the goods, new you looking to producers, season could could in all the you're how affect Dakota including looking how U.S. region factors consumers and wheat result increased in we're spring what at been of noticing launch? say As macroeconomic inflation on And due including at have such as in technologies the you North commercialization? starting are at food, thinking

Okay.

going is that So please is the when eager this yield their usually increasing the are increase is up. remember profit price market And of are yield. and always to crop, first to the that increase we the going looking product that price something yield for. And farmers of launch the

the price yield we result And is which for are the of now positive -- wheat. because to are in So going price on wheat wheat what's situation for in because increase situation currently the of wheat Ukraine, targeting the going the the up.

the according well, interested in. have farmers in So to the yield the you because so been going are the will everything, your protection will you if of as season something lot yield give we investing wheat. that your to a can increase in of publicity and crop price your is the up in And it's that always of interest crop, when increase

product will the next year, evaluating year see week And wheat because production of can this during it's year So the due is in wheat that if for is why this bottom that on to what's the one we now very are think things for yield we for same increase probably I next trend the world. also price positive. line, going and capacity

nice demand. increase the be think should capacity lead our to try to I So year production it it for believe that XXXX. I could -- a will we

can such yield we -- sorry. crop wheat, for So such improve as performance as a further yield

maybe question. one more All right. And just

the Corteva partnerships You addition additional ongoing partnership. in mentioned AgPlenus looking at to potential

a that bit Corteva be talk and and give us a a in for of partnership? general little bit little color looking the on could could different you weighing potential So factors perhaps perhaps

to on again company. advantage once very to the question new Amber, Brian CEO excited this of take that like Dr. have we and would the are I say First,

I looking of we think activity forward see next to with are addition in short herbicides. take company started of from excited area that the think quite to to about to how the I'm and to going he's working level. him, doing expand in time to He already how the what the

really progress to for previous of see so -- looking them area how So his on in the herbicides. herbicides. look question, targets of the forward our we as that respect a your of few within guidance. shared presentation -- we under I'm And a few AgPlenus developing in With target listed company pipeline the to we of targets in our [indiscernible]

except them share to of we course going from some information. this And much respect our expectation expanding are on we we type of to relationship part disclose and pipeline, Corteva, of And today according plan. to can't are need partner's in our this what's with not that

looking to that started we to and are that our of to actually something X -- the have APTH they to and information information target, managing the the are that's that different from the [indiscernible] just we one addition target. gather and additional types talking indication In targets They guiding looking we And this [indiscernible] protein. are is in for they're on pipeline. companies which of that the is external are of specific more information, targets a and chemistry group a it. with new looking that this molecules is we and around something is apart abiding which we this internal with are, show gather that of we again not Corteva, learned, them lot already relationship around

This And focusing I information of target what later are we additional this in different is is will world-leading the that again, type So data this with of we create gathering lead action, one and relationship. to collaboration at very this that develop is will are interesting the for with of around that is validate on to information on target are a information And new assuming emphasize doing. [indiscernible] companies, this specific herbicide. interest which AgPlenus sharing generate of we and I generating chemistry that what type chemical ag the And again the we is target. And now on to enter type to the of enough believe of and our into that these that mode request this protein. company. that could something the time now we're specific on information that and we is area which is focus [indiscernible] think we

is again, this biology, are collaboration we'll a show our we could chemistry, act later their to And a lead why on already with for, So ability if -- of leading this it's different one nice chemistry it's we that, result around looking indication discovered around believe we that to the it as have protein. the assays in that a herbicide.

is question next The from Nathan Weinstein Capital. Aegis of

a types. start broad inhibitors shown have solid tumor range just Checkpoint out maybe of can Biomica. I efficacy in So on

the criteria curious inclusion or types certain of all-comers? I'm cancer specify So BMCXXX upcoming just of the which for study of

BMCXXX? validate is Your going type the cancer question we are to what that of

Yes, exactly.

Yes.

wrong, I kidney in So my think a lung, it's skin, that mentioned not that I'm script and melanoma. if I

Okay.

in that question, launch, have of prepared maybe for thanks this so in to beyond revenue Israel? remarks, speak must me. first what And then XXXX? we shifting the other be reminding just track to to of the you I the the the at should metrics second progress could awareness consumer looking for in example, far the And considering Canonic, but missed So products early stage gears trend

Yes.

product the Canonic a of for our -- -- we Europe. so the smell main and will is in and driving second that XXXX itself. market. MetaYield think in it But we at in and come really the from is look concentration least the THC of will the why that be will quality I mainly Israeli And and from come [indiscernible] the are expectation from this market [indiscernible] the looking feel growth family. And product not my the is Israeli

that we we is focused are expecting product family to in on, are the Precise, think which family, second launch I the which which XXXX.

of on this products start a see And is type indication the specific relevant disease. way. the significant here indication, in to effect we cannabis medical product to specific I of talking pain the could cannabis will this the that where that market I on a think we going about or up European medical clear that very are is with -- revenue where be more think

to So be when what really is reasonable think a making Canonic's the THC market see can Israeli additional from Precise also the see our include yes, -- those we we can family won't but in ready revenue differentiate and products But we I introduce not will and big think in activity will be companies will and the will it this Israeli mature. we the And future I for products. then from a when probably Israel. other way and Europe. and [indiscernible] just what CBD, to market mainly just with should be the parameters I that definition market

So we market, to MetaYield my on shorten with will still year focus XXXX product. answer, the Israeli the

market THC come I the Precise in to product Israel. their Europe and main family. will wave second The with believe higher that from share is the But expected growth, of capture it from

Stephen from comes Goldman [ph]. question next The

Okay.

a program, subsidiaries. about have generally each questions So main your about X very some of and plans, about financial briefly, couple I questions CRISPR of a have question your your I then

shareholder raise plans or the So has value I with subsidiaries. aspect, you past, respect December your not by as of mood to of unlocking the lately. discussed approximately one the $XX market know have we've you've in been XX, and if financial doing to In whole more biotech that IPOs the as positive there money. a heard are million

to plans do So have do you still that?

or partners current we [indiscernible] of of or of our institutions the should market the investors, then be our strategic proposal -- regard, technology they current consider direction stabilize. I [indiscernible] financial for I realm and capital the institution. prefer main that believe investors, existing at but well. potential subsidiaries strategic be when into And a looking with in look it only margin investors market course, the I at a private we on to public it partner this some think think the with see course of step and we should [indiscernible] will will stage then that we the of focus financial is relevant start With value there could the private if And that as will this start next will conditions. And stage the be capital offering.

progress from that I the when that the especially start of for increase importance think really company. is like to these trend. food days the issue more see -- is their [indiscernible] and to the stability, positive potential will to my to world to supply impact think And of companies forward this show I activity perspective, looking it understanding how awareness the the to of in advance I'm

when looking coming And and we and think to X, so reach have to interesting point take the start the results company achievements company in evaluate begin funds believe [indiscernible] when the we point to always the to about to this market, is talking trial, be some to a private this -- earlier. clinical it's And public. could from take would you're [indiscernible] money I opportunity But the they to the very between you that I to opportunity [indiscernible]. described public the like the you also really raise I are still in the if interesting -- this when this have to

at you raising you subsidiary say that, Now talking are when level? about money the

Yes.

less view comment Any actually -- than itself. of it's that would the Okay. dilutive. All the view Evogene that my right. it be presumably Is certainly subsidiaries the higher your on value each that? of Because could be value that of

I that can like comment this. something sure not I'm on

imagine between of we is slide the -- company's presentation leading in valuation our are -- published that company in this our in there of they could, one valuation call where the one this could we our that subsidiary. same can in today, message the core to it highly a or public they the the money. review, be You the do everybody which I current what was believe segment, what our I valuation subsidiary, last comparison take and raised recommended on is time that that as each And [indiscernible] could CEO what if subsidiary the some

focusing the should that it the is an of completely something give but Of the what you this market and cap give capture be is on it will the to could helps to be our you like [indiscernible] are not Evogene money. that course subsidiary current can to to the but No our on. it value we what value, need still our really doubt you subsidiaries now that that's what the of what independent real an if company of could you indication compare we be they maybe can raise indication where if are, or be between make subsidiary sure subsidiary

have of including Briefly release, Evogene's that in release products. that any involvement the Dr. discussion your past And with VP with CRISPR-IL at on who And November, is there the is Can been development consortium. CRISPR you has Emmanuel, specifically what press Chairman in that you New our shed I using Directions in I light Okay. understand on CRISPR. consortium. by press that? in the new you is happening some the actually the know Evogene of role of

and is you described consortium called the of companies the this are on CRISPR-IL, correct. academic Evogene which it's in now technology Israeli largest is is of actually funded First, the developing that area and [indiscernible] breakthrough involved consortium everything and the editing, innovative government. by genome and biggest, institutions focusing leading

human is [indiscernible] using piece developing very which are in of or RNA, I efficiency in [indiscernible] accuracy we called think mainly all the and plants animal. editing from in important consortium. what consortium, this machine, or Israel is the leading this to a ensure genome very, guided in And -- in AI

the that Evogene, technology it's doing. involved but previous are just are advancing right developing almost not in last a looking And it's [indiscernible] inclusive And it's in doing. last very rights, [indiscernible] necessarily of And rights, in, we work to is have we're at we and we nicely. -- really we important quarter the of we own have year. So the the that

that announced extension We X.X Israel by the another approved of years. also consortium the government

for that all can world the commercialize it something there. is developing are we industry. to unique passed this agriculture of going we that is how what So is this the the in for of food engine. we the are products And activity, we evaluating. we What activity value ag doing -- this from are sure tech generator, now and I'm use this our

is we information. here nice the to a medical and if it to And also build type very a treatment. one the is next we And like able the when would okay, we But [indiscernible] industries, internal But because of provider we technology share to the discussion to ask more to probably really financial so that to will of clear be we ourselves what unique get avenue, the try that ourself, questions, have technology big, to something sure develop -- happen. something very, be also we resources You performance. other potential this me the are is different show or will service and need is many very make to to this asking finalize can if we Still, not enough it is to there use is that would make we very products. step?

regard. So this is with where we today this are

yet little that for your you you Bristol to on expect haven't your release trial I although into design? seen design I'll been their with details expect trial the entered inhibitor a of first to move you dose disclosed the Myers And patient? Okay. secondly, checkpoint But have BMCXXX, do PD-X to on And touched agreement bit this. think But supply we when do you've Opdivo. when for has a Biomica.

[indiscernible] together is I And they what I think I before joint joint it'll that this honestly, didn't Probably think person information. between checkpoint need in with to second certain with treatment this there directly maybe they're to you we is to do. the the I of this don't to I the the will include another enter the I'm will discuss your they like do that question to XX BMCXXX we -- not sure to trial of treatment. our and to Biomica part? don't have information. a the is high this can like this would Elran, will so. we then to toughest ask. receive do the to all BMCXXX while know the even that something respond the XX In cycle that days disclose positively by know was this level, And is they right to are of recruit Opdivo. this also we that receive CEO if or And treatment, was don't So planning I And you or question. inhibitor. But go initial think disclosed going are to going all a XX Biomica's time information patient what

the Yes. patient? expect When of first the you do dosing

believe I second quarter, beginning the the quarter. first the of that in in be the quarter, at the beginning, it'll Yes. second

real that joined of Segal work. And great. got science become guess had Twitter Eran few specialty scientific his That's Dr. He's I following Israel, right. because your recently, All has star he's I a but announced a on ago, Segal Okay. then in months a in you Dr. coincidentally therapeutics. committee. been advisory microbiome

lab be, -- in active his role And a will playing or so an Biomica? he be having my quite is

very interesting on Biomica his ways and is lab Segal's prize really that Nobel sides lab. And if I I winner. light a and Eran right, Evogene, discuss will with what between And Yonath really to there to to and a to hopefully focusing working green joined think Eran of find he's is lab, of microbial be scientific world, in field is Ada world together can amazing. he there area for can I give lab work It evidence leader important is focusing we doing. both that and we together. are his you're yes, mean, work already ongoing with in board what know Ada I quality where his advisory optimization and the the the we on in together, the nice phase, is between Segal mainly mainly we synergy and discussion and what work is [indiscernible] yes, our competitional first, to are we yes, also are a very in doing of but strong Professor on we unique phase the So the are activity. effort lot And what which and phase. are, the lab are on very discovery while development focusing And Biomica work genomics discovery Yonath's we [indiscernible] Evogene. in is our that Biomica

also how this now quality Biomica lab, and and to serious compliment in of way with another nice the the [indiscernible] and Segal's very company So Eran people it'll to be accomplishment

quite He's great. That's an impressive gentleman.

to Let the I'm so and me going announce and search wondering to understand currently Bio, when a move CEO. I you appointment CEO, new how Lavie the expect for you're -- that new on looking a is of

to take in chairman, to something and that managing doubt we that So look upcoming, we next officer, working now think role acting company we acting they the believe are [indiscernible] bring when are business Currently, [indiscernible]? that look to chief it. I'm I a are we we one CEO. few announce And the So and headhunters starting the and no And as right months. interviews. -- believe have with we'll you [indiscernible] we are the the places. deal right we conduct it's I to in the that the next are questions but but the and should according we have the is both decided I -- of also need find really, we person to my to company temporary we the should plan will target,

the can I hopefully is And the take it's [indiscernible] one also of of that the company to -- want right going person one next be public bring to to [indiscernible] So the really the phase. market. to to

are for for task. experience the this we has looking also So somebody right type of that

during to search. the That's we the forward Okay. look of results what successful

a much the such doubled your price your because unfortunate that had has it's invasion and in My of with price in understand understanding Ukraine wheat price exporter, year. And of is skyrocketed. wheat. you I the of the the pretty since being mentioned, Ukraine wheat Russian that -- I of last major actually speaker guess, So last

double marketing increasing $XX? how of way net about increasing affecting by So in in on affecting because this is figure now last acre kind to per about marketing acre. net now you're result, campaign? revenues this were -- you -- is ground And results fall per $XX you Is the the your that I and talking know how

this process start [indiscernible] we in for marketing So XXXX. the year,

going to an X and at month, place So that quantity is on sell. won't event usually that least months in something effect we the This the that pricing preparation to it produce the have you last the [indiscernible] before. took and

could we be of will I production force Lavie a we the more the effect generate are to capacity, the is the price an grain think and this if we be Bio is, also to it's a So parallel about next where because see increase operational the that during significant task price price. it the it'll talking the in large because year the that wheat sales effect, you season product and and capacity, we XXXX, increase are increase the microbe on of need for quantity, it an we microbe. right going underestimate the production -- shouldn't issue is our to the then in this the if should can wheat you one on produce team, the And capacity, main find can the party sure probably to I third because have think the make that that of for challenge

So that it where to have first, the can sure right stay is grain capacity need [indiscernible] we we that make price will now.

Well, sense. that makes

the or in Manitoba, it like North the expanding parts only launched Canadian you Saskatchewan. XXXX you're X XXXX know And to Dakota. of in I launch, in your and year, the to respect next presentation, provinces, for with Alberta So North according Montana looks Western and Dakota

still is all, you Canada? Like, states beyond you next the that and X those your planning are going example, for expand And to question provinces plan? of expand in are is, to Europe? into First X

be we to market means initial to European like markets. to to which now world, Europe a the going plan to penetration, the expand as to United and maybe so different you these might product Canada. regulatory application accelerate way and see, would is also will also planning start will we Canada. plan, approval let's the to presented, longer States let's is and So there a it an on submit original and in in the the bit But process accelerate our because little [indiscernible] U.S. what's due see. it to change we take in were the from days mainly the But

there are the and your Okay. and filings Europe. with launch. But mentioned being United California. to your in you you've markets about in you've then filings talk And XXXX commercial presentation indicated America that only North respect regulatory doing of in the States anticipation a you LAVXXX, in XXXX But

other be to you those? will in Canada Europe? the so, states, So when you regulatory in do filings if do in And expect and provinces doing

U.S. one process time the approval we So shorter such previous than in based is to Europe. [indiscernible] experience, But in like initiate the for more the a market in than much on product regulatory place. needed to

and course all is Actually, and are believe for probably we level, launching in product in our the -- we Europe. to the will this we conducting also target it But trial that Europe product states in U.S. California and is U.S. the the So field expand initiate we that the or U.S. commercial probably Italy, of in the Coast we started in in in in other -- the in West Europe,

first mainly be will to process. will process, country start would be U.S. probably see But able this like X of other we as product because to continents regulatory marketing the So these the that in yes, continents it and the well. we

Okay.

Bio is by about I was multinational So your Bio other compared agricultural guess XX% company, interesting actually the owned spin-off Corteva, Lavie that DowDuPont. what's of of to is a subsidiaries which Lavie

operations in to would is Corteva the involved and how willing additional provide of So they be Lavie Bio financing.

He So representator Corteva. Bio ag activity Corteva biological the in Lavie in Board. has a leading is

knowledge And really a as really member. having see having huge And I him. he's enjoy So of I with the things positive in a I lot working him find -- field. board

so collaboration X really I have is Corteva of teams, advancing in, think there each And nicely. different to that I there in companies would is corn world type secondly, working both product be you coming this it's products. if will that work think, you X the from like I on with. implication to soybean, We believe are one would And only probably and with there activity. for ongoing a And other. high

them are the we are And working is working one are very we of with is that Corteva. with second proud them Bayer together. One we Corteva and and very,

their level, which which so by to and ROE a is product be involvement commercialized a also that Corteva. will in Board materialize to be great, [indiscernible] the and [indiscernible] is level So in will really will partner the -- marketed commercial

Okay.

November to of on guess think XXXX. language molecule company X of talked about -- that not AgPlenus. the -- move I lead. me the And Let And to But today, In and the an always past, had you being but becoming stage has a your used. you've referred there's obtaining lead announced APTH I I optimized different next becoming status. in

optimized is becoming in is APTH still -- an in plan X it sometime becomes lead So the XXXX? that

Okay.

there other later we like would probably we'll more and still address are will to let can offline have question. question, some and But be So I bit if elaborate thank an on definitely about discussion, that to happy also you all and to some people it. little I for this the on hope other even your I more a of I call, people questions think ask

target. a interest AgPlenus, there, that which the currently see there the they to looking to more have. focusing you they this So with death at [indiscernible] is that on has blockage wheat. product big -- we necessarily, are with improve a a is you things And information respect of its a a companies other that interesting package protein. so no like like words, talking not is commercial protein nice is leads of [indiscernible] that is on performance, show a single to are the evidence targeting to it their specific would on And specific few is on be would when But In that and molecule with a much learned they specific but this only activity a ag protein, are the molecule the one that target, the protient. chemical

about groups protein. chemistry think new action have with see new mode have a that specific of efficacy to that we they [indiscernible] see to will following, a the to So to they few protein, respect this plus of have some show

next to phase what day to in. this that order we of really package are in build trying move we this are the So doing collaboration [indiscernible] type is to interested

they we was why -- that are and still So have the And important which have it's X binding higher or much is a day what X days these our learned nice package reach the product to are at protein. and success This yes, But phase to spending indication. big to advancing phase. than to commercial chemistry. only [indiscernible] previous or adjusting [indiscernible] -- so only the experience the chemistry we the same because you end leading APTH group to even from also we a the from company X. the of of or AgPlenus, is when such And you [indiscernible] are to all now leap chemistry [indiscernible] resources focusing to

more the cloud molecule like protein focus to interesting binding because changed interesting protein -- here. was industry this from that is we a on our are So it and of single a [indiscernible] to chemistry what

why a terminology on are So this build package specific the we than protein how we rather today and around is to changed a chemistry. all a focusing

is Janney Scott. Brett question of next Montgomery Reiss The from

kind Or use it that prescription once using start it, prescription, a to repeat use? that of one-and-done and GXXX of a GXXX patients some use is kind for they it is The cannabis they time? start the product, quite

that So chronic renewing it's and disease. prescriptions, pain, again usually a patients they month and chronic literally again are it are again, receiving every

saw what again. our they [indiscernible] patients products it's So meaning the go the that brought brands which a doctor again and that specific is to And in good few buy time, available to that be -- they continue GXXX news that and to they so. first they [indiscernible], is in category, is could receive the cannabis one buy for And respect of from can we each the few is that prescription is a not continue the product especially product, are type, with there there products. called buy for for the category. product

will cannabis month, patient, the from move to do every to they and brand buy yes, they're So but another one brand allowed they can so.

And what question. that is especially as to once product I I continue is [indiscernible] addressed buy your So a very positive they we news month. that said, people hope saw that GXXX every

Is in I your I decides Dakota. Right. they've of the Right. a what to works typical getting mean, North not that the way? your Then lot in sales that try spring feedback counter, farmers suppose typical they crop farmer use is with resistant their crop from to sales with wheat, and your sales shown I'm it to not it, interested before use in that? it it? the to see they it. points? is Is any want What's it farmer's maybe afraid that a price? it people's just distributor do you're it resistance? just counterargument respect The hurts every Are they And to fellow farmers what

I and don't was [indiscernible] our I the information. year, we -- the product. sales -- the I planning information and make it the we do you were situation. have that to It is because we all quantity we have to reputation the this how still have a are full we to to see reason we this make going will use year that What tell to wanted not product, that control right first you sure want huge. because produce the wasn't the don't So building to that sure so I can all are if quantity, our on tell to wasn't what

has obstacle. product in just try farm. after the for so on buy the of significant the first are on this the of buy part it difference. -- from information going And a to that a -- product and the they time. See, is they replace that what then a a such to doing, to It's can The a main product, people positive this buying usually need quantity can for then much if specific of it buy field so, And they basis effects to to the the you need not educate field. need are of in first a and enough portion to they the the make this farms. give farmers they effect, a that regular all year one, then [indiscernible] start And for are

is that [indiscernible] I'm what for So quantity. see initial hard that problem saying me to it's to people want to our sell

will about a I ag on what is which validation how we the when have biological impression think important is then activity. is that after. And And that validation on you talking year very a you the based significant growth microbe. a in -- This is their especially to you're product introduce new usually market. good see living

Right.

for decide to is the Ofer, buy open management market, that? they do on to open and window stock Okay. the Board upper members should

with can it attorney. we it checked I currently And want Well now. We [indiscernible]. do we [indiscernible] can our

Not really holders you. the just some out that purchases. for stock, of question, see there of retail-type I but a the lay when bolstered they their insider up is morale

Okay.

time. no this at are questions further There

In U.S., of please Mr. Mr. to please to a concluding you statement, statements? hours would this to ahead scheduled Haviv, Internationally, remind his after like XXX-X-XX-XX-XXX. that like would call X the participants closing is please Before Haviv call conference. to XX-XX-XX-XXX. In make I X-XXX-XXX-XXXX. replay go begin call with Israel, the Ofer your call in ask I

like participating you course, for would more of forward I I'm happy you thank progress. Evogene's you. in you on be than call. And this really for to Thank will everybody once thank continue to update Yes. achievement, and looking to analyst our we again.

you. Call. participation. Thank Quarter Evogene's your you Conference Fourth XXXX for concludes Thank Results This

go may You ahead disconnect. and